Molecular typing relies on molecular genetic testing and is not yet routinely offered. Molecular subtypes and immunohistochemical surrogate markers in the tumors (HR, HER2, triple unfavorable) correlate in about 70%. The differentiation of luminal A and B subtypes by HR standing and proliferation markers like Ki-67 can be handy, but a potential val